博动醫學獲美敦力領投 1 億美元融資
Pulnovo Medical secures $100 million in funding led by Medtronic
介入心臟病學先驅 Pulnovo Medical 近期在超額認購的戰略性融資中獲得了 1 億美元資金。
Pulnovo Medical, a pioneer in interventional cardiology, recently secured $100 million in an oversubscribed strategic financing round.
這筆重大投資由醫療技術領域的全球領導者美敦力 (Medtronic) 領投。
This major investment was led by Medtronic, a global leader in medical technology.
除資金挹注外，兩家公司還達成了一項商業協議，共同探索未來的市場機會。
Along with the funding, the two companies entered a commercial agreement to explore future market opportunities.
Pulnovo 成立於 2013 年，專注於肺動脈去神經支配術 (PADN)，這是一種透過標靶神經來治療肺動脈高壓的微創手術。
Founded in 2013, Pulnovo specializes in Pulmonary Artery Denervation (PADN), a minimally invasive procedure targeting nerves to treat pulmonary hypertension.
該公司已完成了約 1,500 例手術，目前正積極拓展全球版圖。
With about 1,500 procedures already performed, the company is expanding its footprint across the globe.
Gregg Stone) 博士領導的兩項 IDE 臨床試驗。
Gregg Stone.
此次合作對 Pulnovo 而言是一個關鍵轉折點，標誌著該公司從一家以研究為導向的初創公司轉型為全球醫療器材廠商。
This partnership marks a pivotal transition for Pulnovo, moving from a research-focused startup to a global medical device player.
這筆新資金將用於加速臨床試驗並強化國際商業基礎設施，這顯示了市場對其專有技術的高度信心。
The new capital will be used to accelerate clinical trials and enhance international commercial infrastructure, signaling strong institutional confidence in their proprietary technology.
